Clinical Trial Goal
To find out:
- The highest dose of DFV890 that's safe to give
- If DFV890 is safe and works well to treat very low to intermediate-risk CMML or MDS that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have CMML or MDS that has relapsed or is refractory, and that doctors consider to be very low to intermediate-risk
- Have not been treated with a drug that targets NLRP3 or IL-1. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
DFV890 is a small molecule inhibitor that targets NLRP3 in certain cells.
You’ll get:
You’ll get:
- DFV890 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to about 1 year.
The Food and Drug Administration (FDA) has not yet approved DFV890.
Contacts
Novartis Pharmaceuticals, 1-888-669-6682, novartis.email@novartis.com
Novartis Pharmaceuticals, +41613241111
Locations
Sponsors
lead: Novartis Pharmaceuticals
